Search by Title Article Topic - Any -AdvocacyAnnual Scientific MeetingAwardsBoard Certification ReviewCertificationClinical DocumentClinical TrialsCoronavirusEarly CareerFellowshipFuture LeadersHeart Failure Awareness 365Heart Failure GuidelinesHF Research FoundationHFSA CommitteesHFSA Comprehensive Heart Failure ReviewHFSA Learning CenterIn The NewsIndustryJournal of Cardiac FailureLeadershipMembershipMentorshipNursingPartnersPatient ResourcePatient StoryPodcastsPresident's UpdatesPress ReleaseProfessional DevelopmentProvider EducationResearchSocial MediaStatementSubmissionsWomen in Heart Failure Article Type - Any -HFSA NewsIndustry NewsPatient NewsPractice News Sep 25 2022 | HFSA President's Update: September 2022 HFSA News President's Updates Read More Sep 19 2022 | Protecting Your Heart and Your Loved One’s Hearts with Genetic Testing Patient News Heart Failure Awareness 365 Patient Resource Read More Sep 8 2022 | FARXIGA significantly reduced the risk of cardiovascular death or worsening of heart failure in patients with mildly reduced or preserved ejection fraction in DELIVER Phase III trial Industry News Industry Read More Sep 6 2022 | Bayer’s KERENDIA® (finerenone) Receives Updated Label to Include Findings From Phase III FIGARO-DKD Cardiovascular Outcomes Study in Patients With Chronic Kidney Disease and Type 2 Diabetes Industry News In The News Industry Read More Sep 1 2022 | Heart Failure Awareness 365: Types of Heart Failure and Related Conditions/Diseases Patient News Heart Failure Awareness 365 Patient Resource Read More Pagination First page « First Previous page ‹ Previous … Page 32 Page 33 Page 34 Page 35 Current page 36 Page 37 Page 38 Page 39 Page 40 … Next page Next › Last page Last »
Sep 19 2022 | Protecting Your Heart and Your Loved One’s Hearts with Genetic Testing Patient News Heart Failure Awareness 365 Patient Resource Read More
Sep 8 2022 | FARXIGA significantly reduced the risk of cardiovascular death or worsening of heart failure in patients with mildly reduced or preserved ejection fraction in DELIVER Phase III trial Industry News Industry Read More
Sep 6 2022 | Bayer’s KERENDIA® (finerenone) Receives Updated Label to Include Findings From Phase III FIGARO-DKD Cardiovascular Outcomes Study in Patients With Chronic Kidney Disease and Type 2 Diabetes Industry News In The News Industry Read More
Sep 1 2022 | Heart Failure Awareness 365: Types of Heart Failure and Related Conditions/Diseases Patient News Heart Failure Awareness 365 Patient Resource Read More
